Literature DB >> 25473061

Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Annalisa Meola1, Alexander W Tarr2, Patrick England3, Luke W Meredith4, C Patrick McClure2, Steven K H Foung5, Jane A McKeating4, Jonathan K Ball2, Felix A Rey1, Thomas Krey6.   

Abstract

UNLABELLED: Neutralizing antibodies (NAbs) targeting glycoprotein E2 are important for the control of hepatitis C virus (HCV) infection. One conserved antigenic site (amino acids 412 to 423) is disordered in the reported E2 structure, but a synthetic peptide mimicking this site forms a β-hairpin in complex with three independent NAbs. Our structure of the same peptide in complex with NAb 3/11 demonstrates a strikingly different extended conformation. We also show that residues 412 to 423 are essential for virus entry but not for E2 folding. Together with the neutralizing capacity of the 3/11 Fab fragment, this indicates an unexpected structural flexibility within this epitope. NAbs 3/11 and AP33 (recognizing the extended and β-hairpin conformations, respectively) display similar neutralizing activities despite converse binding kinetics. Our results suggest that HCV utilizes conformational flexibility as an immune evasion strategy, contributing to the limited immunogenicity of this epitope in patients, similar to the conformational flexibility described for other enveloped and nonenveloped viruses. IMPORTANCE: Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), and neutralizing antibodies play an important role in controlling the replication of this major human pathogen. We show here that one of the most conserved antigenic sites within the major glycoprotein E2 (amino acids 412 to 423), which is disordered in the recently reported crystal structure of an E2 core fragment, can adopt different conformations in the context of the infectious virus particle. Recombinant Fab fragments recognizing different conformations of this antigenic site have similar neutralization activities in spite of converse kinetic binding parameters. Of note, an antibody response targeting this antigenic region is less frequent than those targeting other more immunogenic regions in E2. Our results suggest that the observed conformational flexibility in this conserved antigenic region contributes to the evasion of the humoral host immune response, facilitating chronicity and the viral spread of HCV within an infected individual.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25473061      PMCID: PMC4338873          DOI: 10.1128/JVI.02190-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Efficient method for production of high yields of Fab fragments in Drosophila S2 cells.

Authors:  Marija Backovic; Daniel X Johansson; Barbara G Klupp; Thomas C Mettenleiter; Mats A A Persson; Felix A Rey
Journal:  Protein Eng Des Sel       Date:  2010-01-24       Impact factor: 1.650

2.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Authors:  Michelle C Sabo; Vincent C Luca; Jannick Prentoe; Sharon E Hopcraft; Keril J Blight; Minkyung Yi; Stanley M Lemon; Jonathan K Ball; Jens Bukh; Matthew J Evans; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.

Authors:  Laura E McCoy; Anna Forsman Quigley; Nika M Strokappe; Bianca Bulmer-Thomas; Michael S Seaman; Daniella Mortier; Lucy Rutten; Nikita Chander; Carolyn J Edwards; Robin Ketteler; David Davis; Theo Verrips; Robin A Weiss
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

5.  A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Authors:  Zhen-Yong Keck; Oakley Olson; Meital Gal-Tanamy; Jinming Xia; Arvind H Patel; Marlène Dreux; Francois-Loïc Cosset; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

6.  Production of recombinant antibodies in Drosophila melanogaster S2 cells.

Authors:  Daniel X Johansson; Thomas Krey; Oskar Andersson
Journal:  Methods Mol Biol       Date:  2012

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Dhanya Jayaraj; Richard J P Brown; Timothy P Hickling; William L Irving; Arvind H Patel; Jonathan K Ball
Journal:  J Gen Virol       Date:  2007-11       Impact factor: 3.891

9.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

10.  Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Judith M Timms; C Patrick McClure; Richard J P Brown; Timothy P Hickling; Thomas Pietschmann; Ralf Bartenschlager; Arvind H Patel; Jonathan K Ball
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

View more
  54 in total

1.  Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.

Authors:  Fernando Aleman; Netanel Tzarum; Leopold Kong; Kenna Nagy; Jiang Zhu; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

Review 2.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

3.  Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.

Authors:  Dapeng Li; Markus von Schaewen; Xuesong Wang; Wanyin Tao; Yunfang Zhang; Li Li; Brigitte Heller; Gabriela Hrebikova; Qiang Deng; Alexander Ploss; Jin Zhong; Zhong Huang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

4.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

Review 5.  Antibody-Mediated Catalysis in Infection and Immunity.

Authors:  Anthony Bowen; Maggie Wear; Arturo Casadevall
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

6.  Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Authors:  Leopold Kong; David E Lee; Rameshwar U Kadam; Tong Liu; Erick Giang; Travis Nieusma; Fernando Garces; Netanel Tzarum; Virgil L Woods; Andrew B Ward; Sheng Li; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

Review 7.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

8.  Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.

Authors:  Yili Li; Brian G Pierce; Qian Wang; Zhen-Yong Keck; Thomas R Fuerst; Steven K H Foung; Roy A Mariuzza
Journal:  J Biol Chem       Date:  2015-03-03       Impact factor: 5.157

9.  Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Authors:  Zhen-yong Keck; Christine Girard-Blanc; Wenyan Wang; Patrick Lau; Adam Zuiani; Felix A Rey; Thomas Krey; Michael S Diamond; Steven K H Foung
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

Review 10.  Viral evasion and challenges of hepatitis C virus vaccine development.

Authors:  Brian G Pierce; Zhen-Yong Keck; Steven Kh Foung
Journal:  Curr Opin Virol       Date:  2016-09-19       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.